---
document_datetime: 2024-10-07 10:47:59
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/yuvanci-epar-all-authorised-presentations_en.pdf
document_name: yuvanci-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8729651
conversion_datetime: 2025-12-21 11:13:35.635067
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| MA (EU) number   | (Invented) name   | Strength      | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Pack size                  |
|------------------|-------------------|---------------|-----------------------|---------------------------|-----------------------|----------------------------|
| EU/1/24/1859/001 | YUVANCI           | 10 mg / 20 mg | Film-coated tablet    | Oral use                  | blister (alu/alu)     | 30 x 1 tablets (unit dose) |
| EU/1/24/1859/002 | YUVANCI           | 10 mg / 40 mg | Film-coated tablet    | Oral use                  | blister (alu/alu)     | 30 x 1 tablets (unit dose) |